company background image
GMT

Genomtec WSE:GMT Stock Report

Last Price

zł6.99

Market Cap

zł57.0m

7D

-3.1%

1Y

-52.1%

Updated

22 May, 2022

Data

Company Financials
GMT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

GMT Stock Overview

Genomtec S.A. manufactures mobile molecular analyzers using molecular diagnostics technology worldwide.

Genomtec Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Genomtec
Historical stock prices
Current Share Pricezł6.99
52 Week Highzł14.98
52 Week Lowzł6.00
Beta0
1 Month Change-1.83%
3 Month Change-29.04%
1 Year Change-52.06%
3 Year Changen/a
5 Year Changen/a
Change since IPO-48.41%

Recent News & Updates

Shareholder Returns

GMTPL BiotechsPL Market
7D-3.1%-1.7%0.9%
1Y-52.1%-40.0%-15.6%

Return vs Industry: GMT underperformed the Polish Biotechs industry which returned -40% over the past year.

Return vs Market: GMT underperformed the Polish Market which returned -15.6% over the past year.

Price Volatility

Is GMT's price volatile compared to industry and market?
GMT volatility
GMT Average Weekly Movement8.7%
Biotechs Industry Average Movement8.7%
Market Average Movement7.7%
10% most volatile stocks in PL Market14.8%
10% least volatile stocks in PL Market5.1%

Stable Share Price: GMT is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: GMT's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201620Miron Tokarskihttps://www.genomtec.com

Genomtec S.A. manufactures mobile molecular analyzers using molecular diagnostics technology worldwide. The company’s flagship mobile diagnostic platform is Genomtec ID, a diagnostic device that is based on the amplification and detection of specific DNA and RNA fragments. Its Genomtec ID analyzer allows the company to test and diagnose viruses, bacteria, mutations, fungi, and parasite infections.

Genomtec Fundamentals Summary

How do Genomtec's earnings and revenue compare to its market cap?
GMT fundamental statistics
Market Capzł57.03m
Earnings (TTM)-zł5.27m
Revenue (TTM)zł218.76k

260.7x

P/S Ratio

-10.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GMT income statement (TTM)
Revenuezł218.76k
Cost of Revenuezł673.26k
Gross Profit-zł454.50k
Other Expenseszł4.82m
Earnings-zł5.27m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 27, 2022

Earnings per share (EPS)-0.65
Gross Margin-207.76%
Net Profit Margin-2,410.43%
Debt/Equity Ratio12.1%

How did GMT perform over the long term?

See historical performance and comparison

Valuation

Is Genomtec undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


23.01x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GMT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GMT's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: GMT is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.

PE vs Market: GMT is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GMT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GMT is overvalued based on its PB Ratio (23x) compared to the PL Biotechs industry average (4.5x).


Future Growth

How is Genomtec forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genomtec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Genomtec performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-212.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: GMT is currently unprofitable.

Growing Profit Margin: GMT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if GMT's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare GMT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: GMT has a negative Return on Equity (-212.77%), as it is currently unprofitable.


Financial Health

How is Genomtec's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GMT's short term assets (PLN2.3M) exceed its short term liabilities (PLN1.2M).

Long Term Liabilities: GMT's short term assets (PLN2.3M) do not cover its long term liabilities (PLN3.0M).


Debt to Equity History and Analysis

Debt Level: GMT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if GMT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GMT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GMT has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.3% each year.


Dividend

What is Genomtec current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GMT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GMT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GMT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Miron Tokarski

no data

Tenure

Mr. Miron Tokarski, PhD, is Chief Executive Officer, Member of the Management Board and Co-founder of Genomtec S.A. His responsibilities within the company involve, among others, R & D and development of i...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genomtec S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Genomtec S.A.
  • Ticker: GMT
  • Exchange: WSE
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł57.028m
  • Shares outstanding: 8.16m
  • Website: https://www.genomtec.com

Number of Employees


Location

  • Genomtec S.A.
  • ul. Stablowicka 147
  • PORT Budynek 2
  • Wroclaw
  • 54-066
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.